亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。
返回搜索结果

Peripherally-Acting Cannabinoid Receptor Agonists for Chronic Pain

技术优势
No centrally-mediated side effectsHigh affinity for cannabinoid receptors
技术应用
Control chronic pain of inflammatory and neuropathic originReduce intraocular pressure
详细技术说明
Dr. Igor Spigelman of UCLA’s School of Dentistry and Dr. Herbert Seltzman, a collaborator at RTI International, have designed small molecules effective in alleviating chronic pain of inflammatory and neuropathic origin without any centrally-mediated side effects. The molecules are peripherally-acting cannabinoid compounds with high affinity for cannabinoid receptors and have been specifically designed to have limited permeability at the blood-brain barrier.
*Abstract

Researchers from UCLA and RTI International have developed novel, small molecule agonists at cannabinoid type 1 and type 2 receptors (CB1R and CB2R) that have low blood-brain barrier (BBB) permeability.  The compounds represent promising therapeutics for treating chronic pain.   
*IP Issue Date
May 23, 2017
*Principal Investigation

Name: Herbert Seltzman

Department:


Name: Craig Shiner

Department:


Name: Igor Spigelman

Department:

申请号码
9656981
其他

State Of Development

  • Compounds with high agonist activity for CB1R and low BBB permeability were examined for stability in blood plasma
  • Pharmacokinetic studies support minimal brain penetration
  • Preclinical trials in rat models of chronic inflammatory and neuropathic pain have been completed and lead compounds have been identified

Background

Current treatments of different types of chronic pain are geared towards decreasing inflammation (if it exists) and maximizing pain relief while minimizing side effects associated with each particular drug type. Unfortunately, this has been a difficult goal to achieve and all of the current treatments for chronic pain, particularly pain of neuropathic origin, have significant side effects which limit their usefulness. Recently, drugs targeting cannabinoid receptors have proven efficacious for patients. However, while current clinical treatments with FDA-approved cannabinoid-based analgesic can provide relief from chronic pain symptoms, these treatments also produce several significant central nervous system-mediated side effects. 


Tech ID/UC Case

23480/2012-715-0


Related Cases

2012-715-0
国家/地区
美国

欲了解更多信息，请点击 这里
移动设备